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Abstract
The Gamma-aminobutyric acid (GABA) system is the main inhibitory  
neurotransmitter system in the central nervous system (CNS) of vertebrates and is 
involved in critical cellular communication and brain function. The endocannabi-
oid system (ECS) was only recenty discovered and quickly recognized to be abun-
dantly expressed in GABA-rich areas of the brain. The strong relationship between 
the GABA system and ECS is supported both by studies of the neuraoanatomy 
of mammalian nervous systems and the chemical messaging between neurons. 
The ECS is currently known to consist of two endocannabinoids, Anandamide 
(AEA) and 2-Arachidonyl Glycerol (2-AG), that function as chemical messengers 
between neurons, at least two cannabinoid receptors (CB1 and CB2), and complex 
synthetic and degradative metabolic systems. The ECS differs from the GABA 
system and other neurotransmitter systems in multiple ways including retrograde 
communication from the activated post-synaptic neuron to the presynaptic cell. 
Together, this molecular conversation between the ECS and GABA systems regulate 
the homeostasis and the chemical messaging essential for higher cortical functions 
such as learning and memory and may play a role in several human pathologies. 
Phytocannabinoids are synthesized in the plant Cannabis sativa (C. sativa). Within 
the family of phytocannabinoids at least 100 different cannabinoid molecules or 
derivatives have been identified and share the properties of binding to the endog-
enous cannabinoid receptors CB1 and CB2. The well-known psychoactive phytocan-
nabinoid Δ9-tetrahydrocannabinol (THC) and the non-psychoactive cannabidiol 
(CBD) are just two of the many substances synthesized within C. sativa that act on 
the body. Although the phytocannabinoids THC and CBD bind to these endogenous 
receptors in the mammalian CNS, these plant derived molecules have little in com-
mon with the endocannabinoids in structure, distribution and metabolism. This 
overlap in receptor binding is likely coincidental since phytocannabinoids evolved 
within the plant kingdom and the ECS including the endocannabinoids developed 
within animals. The GABA and ECS networks communicate through carefully 
orchestrated activities at localized synaptic level. When phytocannabinoids become 
available, the receptor affinities for CB1 and CB2 may compete with the naturally 
occurring endocannabinoid ligands and influence the GABA-ECS communication. 
In some instances this addition of phytocannabinoids may provide some therapeu-
tic benefit while in other circumstances the presence of these plant derived ligands 
for the CB1 and CB2 receptors binding site may lead to disruption of important 
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functions within the CNS. The regulatory approval of several THC products for 
nausea and vomiting and anorexia and CBD for rare pediatric seizure disorders are 
examples of some of the benefits of phytocannabinoids. Concerns regarding can-
nabis exposure in utero and in the child and adolescence are shrill warnings of the 
hazards associated with disrupting the normal maturation of the developing CNS.
Keywords: endocannabinoids, GABA, phytocannabinoids, homeostasis
1. Introduction to the GABA system
Gamma-aminobutyric acid (GABA), an amino acid, is the primary inhibitory 
neurotransmitter in the vertebrate central nervous system (CNS). Although it was 
first identified in plants in the late nineteenth century, only in 1950 was it first 
identified in fresh extracts of animal brain including reptiles, avian, mammals and 
man [1]. It is now accepted that GABA is present almost exclusively within the brain 
and retina of vertebrates and only in extremely limited amounts in the peripheral 
nervous system and other organs of the body. It has been estimated that within 
the CNS, GABA is the neurotransmitter for as many as one-third of the neurons 
with the majority of these cells as interneurons that modulate the activity of neural 
networks. GABA neurons are widely expressed throughout the CNS including the 
cerebral cortex, hippocampus, striatum, substantia nigra, globus pallidus, cerebel-
lum and olfactory bulbs. Within the structures, GABA receptors are found not only 
on the cell membranes of neurons but on supporting glial tissue and astrocytes [2].
As an amino acid, GABA serves other biological roles in addition to that of a 
neurotransmitter. It also functions as a precursor for the assembly of proteins and as 
metabolic intermediary. Despite these multiple functions, GABA is also responsible 
for regulation of neuronal excitability and is the primary inhibitory messenger in 
the CNS. GABA is highly concentrated in the CNS and present in millimoles per 
gram in the brain compared to nanomoles per gram of the more more commonly 
recognized neurotransmitters including dopamine, 5-hydroxytryptamine (sero-
tonin) and norepinephrine [3].
GABA is known to have affinity for two distinct families of receptors similar 
to the excitatory amino acid Glutamate. The first and most prevalent of the two in 
the brain is the ionotropic GABAA receptor, a large glycoprotein of ~275 kDa and 
consists of a pentameric transmembrane receptor typically including two α sub-
units, two β subunits and one γ. Variations frequently occur and may even include 
δ subunit substituted for γ that encircle a central, chloride-permeable pore. The 
GABAA is found on both presynaptic and postsynaptic neuronal cell membranes. 
Upon the binding of two GABA molecules to the extracellular site, the pore opens 
and allows the flow of chloride ions into the cell with hyperpolarization of the cell 
membrane and inhibition of action potentials [4].
The GABAA receptor was cloned in 1987 and multiple subunits have subse-
quently been identified and grouped within seven functionally unique families. 
These multiple isoforms result in a highly complex system of receptors with func-
tions dependent upon the expression of subunits.
Two binding sites for GABA sit on the GABAA receptor along with other sites 
that include a benzodiazepine receptor, a barbiturate receptor, and alcohol. In every 
instance, these binding sites function independently of each other. As a result, each 
receptor does not compete with activation of other receptors and the overall effect 
is synergestic rather than competitive [5].
The GABAB receptor is a second type of receptor and is a metabotropic site that 
belongs to the G-Protein Coupled Receptor (GPCR) superfamily. Pretreatment 
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of isolated tissue from rodent atria and vas deferens with the GABAA antagonist 
bicucullin in 1979 first eslablished that two populations of receptors existed when 
the expected response to GABA was not found [6]. Twenty years passed before the 
GABAB receptor was finally cloned. As a GPCR, this receptor is broadly distrib-
uted throughout the CNS and mediates slow and prolonged inhibitory messaging 
through Gai/o-type proteins. As a GPCR, GABAB contains seven transmembrane 
domains with an extracellular N-terminus tail and acts through a second messenger 
system by inhibition of adenylate cyclase and cAMP formation inactivating voltage-
gated Ca2+ channels and K+ channels [5].
Three receptor subunits are associated with GABAB site. A long, extracellular 
N-terminal called the Venus fly-trap (VFT) domain includes an orthosteric binding 
site, a seven transmembrane domain and the C-terminus tail within the cell com-
prise the GABAB receptor. Ligands to the GABAB receptor have been identified and 
include the selective GABAB agonist Baclofen, various investigational antagonists 
that poorly penetrate the blood- brain barrier (BB) and several allosteric modula-
tors under study [7].
Because of the ubiquity of GABA in the CNS It is not surprising that disordered 
GABA signaling has been implicated in several human neurological and psychiatric 
diseases. Anxiety, sleep, seizure, Alzheimer’s, Parkinson’s and substance abuse 
are some of several disorders suspected to be linked to the GABA system. Already 
several medication classes that have affinity for the GABA receptor, including 
benzodiazepines, muscle relaxants, sedative-hypnotics and anticonvulsants, are 
now routinely used in clinical medicine.
The production, release and degradation of GABA is mediated through multiple 
processes. The main precursor of GABA is glutamic acid, an excitatory neurotrans-
mitter itself. GABA is synthesized by the irreversible single-step α-decarboxylation 
of glutamic acid by the enzyme glutamic acid decarboxylase (GAD), found initially 
in bacteria and plants and then later in the mammalian CNS and retina. There are 
two isoforms of the decarboxylase GAD (GAD65 and GAD67) that are involved in the 
synthesis of GABA with GAD65 closely associated with the presynaptic vesicles. This 
relationship strongly suggests that a coupled process is involved in the the conver-
sion of cytosol glutamate to storage of intravesicular GABA. There are also vesicular 
transports systems termed VGAT for the sequestration of the neurotransmitter into 
the vesicle. VGAT is also the same vesicular transport for another inhibitory amino 
acid transmitter glycine in the spinal cord [8].
Similar to most decarboxylases, pyridoxine is required as a co-factor [1]. The 
localization of GAD in the brain generally correlates closely with the distribution 
of GABA. After synthesis, GABA is stored in vesicles in the presynaptic terminals 
in cells classified as “GABAergic” cells. When GABAergic cells receive a depolar-
izing stimulus, vesicular fusion and exocytosis occurs and GABA is released into 
the synaptic cleft. GABA signaling is primarily terminated by its reuptake into 
both neuronal and glial cells through membrane transporter systems. Through this 
uptake system the presynaptic cytosol and vesicles can reuse GABA. Astrocytes 
also express membrane transporters systems for GABA and play a significant role 
in GABA metabolism. When reuptake occurs in these non-neuronal cells or non-
GABAergic cells, the availability of GABA as a neurotransmitter is reduced [8].
In addition to uptake through membrane transporters, GABA may also be 
broken down by the enzyme GABA Transaminase (GABA-T). GABA-T is, unlike 
GAD, widely expressed in both central and peripheral systems and possibly 
helps limit exogenous GABA from influencing CNS activities. In the CNS, this 
primary enzyzme is associated with GABA breakdown and is found both in 
GABA-ergic neurons and astrocytes. One product of GABA-T is glutamate which 
may be involved in the recycling of glutamate to form new GABA. GABA is also 
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metabolized extracellularly by GABA-transaminase (GABA-T) into succinate 
semialdehyde, which then enters the krebs cycle for further metabolism [9].
2. Introduction to the endocannabinoid system (ECS)
The identification of Δ9-tetrahydrocannabinol (THC) as the psychoactive 
constituent of cannabis opened a door to unexpected discoveries in neuroscience. 
Cannabis is the generic name for C. sativa (C. sativa) or hemp and belongs to the 
botanical group Cannabaceae that also contains hop. Cannabis was found to contain 
numerous molecular structures similar to THC, including cannabidiol (CBD) and 
cannabinol (CBN) and others. These new structures were initially referred to as 
cannabinoids and led to the obvious question of how, and why these botanical 
compounds worked in animals.
It was initially believed that these plant-based cannabinoids like THC, now 
referred to as phytocannabinoids, probably influenced animal physiology through 
a nonspecific mechanism to alter cellular membranes. Soon after establishing the 
laboratory synthesis of THC, modifications of the structure were created and tested 
in the laboratory. The availability of these synthetic analogs of THC led to the unex-
pected finding that the psychoactive effect of THC was stereospecific and occurred 
through binding to an unknown endogenous receptor [10, 11] . Evidence of an 
endogenous receptor was discovered in 1988 that revealed affinity for the THC 
molecule in rodent brain [12]. This previously unknown receptor was named CB1 
and found to be a G-Protein Coupled Receptor (GPCR) with seven transmembrane 
helices. Within a few years, a second peripheral receptor was cloned and named 
CB2. Both receptors in humans were found to have 44% of the amino acid residues 
identical and in the transmembrane crossings 68% were the same. Although CB1 
was the first receptor identified in the brain and was considered a central receptor, 
it is now known that it is widely distributed outside the CNS but at lower expres-
sion, including the respiratory, cardiovascular, skin, ophthalmic systems, and the 
adrenal glands. CB2, originally discovered in the spleen and thought to be a periph-
eral receptor, was later found to be present in limited amounts within the CNS and 
widely available in immune tissue and skin [13].
Although only recently discovered in the late 20th century, it is now recognized 
that the CB1 and CB2 receptors are the most plentiful G-protein coupled receptors 
(GPCR) in the body. CB1 is especially abundant in the brain and is more plentiful 
than all other receptors including GABA.
The presence of these two endogenous cannabinoid receptors led to the expecta-
tion that endogenous ligands must lay ahead. Several years earlier the opiate recep-
tors had been discovered in the brain that had affinity for compounds obtained 
from the opium plant. This led to the isolation of a class of endogenous ligands 
termed the enkephalins that were bioactive neuropeptides.
Soon after the identification of the cannabinoid receptors, the endogenous 
ligand arachidonylethanolamine was isolated in 1993 and found to have agonist 
properties for CB1. This ligand was found in rodent brain and was composed of ele-
ments from arachidonic acid and ethanolamine. This unexpected ligand was soon 
christened Anandamide (AEA), a Sanskrit word for ‘bliss’ [14].
Arachidonic acid is a polyunsaturated fatty acid found in membrane phospho-
lipids in several body organs including the brain [15–17]. In addition to being a 
precursor for AEA, arachidonic acid is also an important precursor for eicosanoids 
including prostaglandins. Shortly after the discovery of AEA, a second bioactive 
lipid that also included arachidonic acid, 2-arachidonylglycerol (2-AG), was found 
with binding affinity for both cannabinoid receptors. Unlike AEA, 2-AG had been 
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known for over fifty years as an intermediary in metabolic pathways of triglycerides 
and other glyceride molecules and is far more available than AEA. 2-AG was found 
to be a full agonist of CB1 and CB2 and abundantly available throughout the body 
[18, 19]. In contrast, anandamide is a partial agonist of CB1 and CB2 and belongs to 
the family of N-acylethanolamines (NAE). NAEs consist of saturated and monoun-
saturated fatty acids that include palmitic and oleic acids and these other NAEs are 
more abundant than AEA but do not bind to cannabinoid receptors [20]. Although 
only recently discovered in the late 20th century, it is now established that the CB1 
and CB2 receptors are the most plentiful G-protein coupled receptors (GPCR) in 
the body. CB1 is especially abundant in the brain and is more plentiful than all other 
receptors including GABA. The observation that the ECS is so highly expressed 
within the brain and the finding that the system is highly conserved in the evolution 
of animals illustrate the importance of the system in the healthy function of man.
Together AEA and 2-AG are referred to as endocannabinoids. These two endog-
enous ligands are produced in multiple body systems and activate cannabinoid 
receptors. These endocannabinoid chemical structures are long-chain, polyunsatu-
rated fatty acid chains and differ significantly from the ring structured phytocan-
nabinoids present in cannabis, with different binding affinities to the cannabinoid 
receptors. The endogenous 2-AG, for example, is a full agonist to the CB1 and CB2 
receptors while the plant-derived THC is only a partial agonist. In addition, another 
important phytocannabinoid, CBD, has even less affinity with only very limited 
binding to cannabinoid receptors. As endogenous lipids, although both bind to the 
cannabinoid receptors, the NAE molecule AEA and the monoacylglycerol (MAG 
2-AG as) belong to two distinct families with different synthetic and degradative 
pathways. Both AEA and 2-AG appear unique among their separate families as they 
are the only molecules that bind to the cannabinoid receptors CB1 and CB2.although 
they share affinities with the several similar lipids for non-cannabinoid receptors. 
In addition, both endocannabinoids and other bioactive lipids have redundant 
pathways in the synthesis and breakdown of the lipid molecules. This diversity in 
metabolism and binding to multiple receptor families by the NAEs and MAG lead to 
a highly complex system that regulates many important functions [21].
Collectively, the cannabinoid receptors CB1 and CB2, the two endocannabinoid 
messengers AEA and 2-AG, and the associated and separate enzymatic systems are 
called the endocannabinoid system (ECS). The ECS is a major system in human 
and the CB1 and CB2 receptors are expressed within the CNS and several peripheral 
organs including heart, liver, fat, skin, eye and the intestines [22].
As details about the ECS emerged during the 1990s and into this century, it 
has become apparent that endocannabinoids interact with several neurotransmit-
ter systems and play an important role in regulating physiological functions. 
Autoradiographic localization of cannabinoid receptors in the rat established the 
rich co-localization of cannabinoid receptors with GABA-containing neurons 
[23, 24]. It has been reported that GABA is produced and released by inhibitory 
interneurons comprising between 20–60% of neurons in some areas of the brain 
[25]. The CB1 and CB2 receptors have been found to be highly expressed in areas 
rich with GABA neurons including the cortex, basal ganglia, substantia nigra and 
cerebellum. Compared to classic neurotransmitters including GABA and Glutamate 
[24, 26], the ECS is far more abundant and widely distributed compared to these 
systems. Thus, activation of the CB1 receptor (the most abundant GPCR in the 
CNS) interacts with adjacent neurons including GABA and regulates neurotrans-
mitter function to express their central effects.
The ECS is also one of the most pleiotropic systems in mammals and differs 
from other neurotransmitter systems in several ways. Importantly, most intercel-
lular transmission proceeds anterograde with the release of neurotransmitters 
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from presynaptic neurons that bind to receptors on the postsynaptic membranes. 
Neurotransmitters, stored in vesicles within the presynaptic cytosol, are released as 
chemical messengers upon activation of the presynaptic neuron. After release into 
the synapse, the chemical messengers are subsequently broken down in the syn-
aptic cleft or taken up by transport systems into the neuron or adjacent supporting 
cells [27].
Endocannabinoids act in the opposite direction from a postsynaptic neuron to 
presynaptic neuron. This retrograde direction allows the ECS to neuromodulate the 
forward direction of chemical communication. Because of their highly lipophilic 
properties, endocannabinoids are not stored in vesicles but are synthesized from 
membrane lipids only when required. Once released, the endocannabinoid diffuses 
to its’ receptor target on the presynaptic neuron and helps regulate overall neu-
rotransmission. In the brain, the presynaptic receptor is predominantly CB1 with 
limited CB2 found in microglia and other tissue. Eventually the endocannabinoid is 
released by the receptor and taken up by either the pre- or postsynaptic neuron for 
final degradation [17].
The endocannabinoids are synthesized in the post-synaptic membrane only 
after the cell is activated and then rapidly degraded after binding to the presynaptic 
cannabinoid receptor, the effect of stimulation is localized and limited in duration 
similar to GABA and other neurotransmitters. In addition, although these actions 
occur binding of AEA and 2-AG primarily to the CB1 receptor in the brain, other 
non-cannabinoid receptors have also been identified that directly bind and are 
activated by endocannabinoids [28].
3. The discovery of anandamide (AEA)
Anandamide (AEA) was isolated from pig brain in 1992 and found to be a 
derivative of the fatty acid arachidonic acid. As the first endocannabinoid to be 
discovered, the molecule was named anandamide after the Sanskrit word Ananda 
that means bliss [29]. As a member of the N-acylethanolamines, it was established 
that AEA shared multiple synthetic pathways with other glycophospholipids [17].
Typical of other neurotransmitters, AEA functions as a chemical messenger 
between neurons. However, there are significant differences between endocan-
nabinoids and neurotransmitters including GABA. Soon after its discovery, the 
uniqueness of AEA was established with the observation that the messenger was 
synthesized only on demand and diffuse across the synaptic cleft in a retrograde 
direction to the presynaptic neuron [17].
Following the inflow of calcium2+ into the postsynaptic cell, AEA is synthesized 
from the precursor membrane lipid N-arachidonyl-phosphatidylethanolamine 
(NAPE). NAPE is present in brain only in small amounts and cannot sustain 
prolonged synthesis of AEA. As with 2-AG, AEA contains arachidonic acid and 
combines this membrane constituent with phosphatidylethanolamine (PE), utiliz-
ing a calcium2+ dependent enzyme N-acyltransferase (NAT). The primary pathway 
for synthesis of anandamide is conversion of NAPE to anandamide through the 
action of a NAPE-specific phospholipase D (PLD), although several other pathways 
are known to exist. Similar to other synthesis in the NAE family, the NAPE pathway 
is not exclusive for AEA. Although the importance of other pathways have yet to be 
established, it is known that in genetically modified mice without NAPE-PLD, no 
reduction of the production of AEA is found [30].
Since multiple pathways may be associated with the synthesis of AEA, the 
abundance of choices has been suggested to enhance the number of stimuli that 
may initiate the production of AEA. Lipopolysaccharide (LPS), for example, is an 
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endotoxin in the outer membrane of gram-negative bacteria that plays a critical 
role in the protection of the microbe. Exposure to macrophages activates LPS to 
defend the bacteria and numerous lipid mediators including AEA are released. The 
synthesis and release of AEA and the other bioactive lipids is not believed to occur 
through the intermediate NAPE but rather through the secondary pathways that 
lead to AEA [20].
The breakdown of AEA results in the release of arachidonic acid and ethanol-
amine. Within the post-synaptic cell, an intracellular serine amidase named fatty 
acid amide hydrolase (FAAH) cleaves the long-chain fatty acid of AEA although 
other available hydrolytic enzyme systems in the cytosol appear to have little effect 
on AEA. Numerous studies have used disruption of this serine hydrolase through 
genetic or pharmacological manipulation to increase AEA activity. Manipulation 
of the FAAH system has already become the target of new drug development in an 
attempt to increase AEA in the treatment of human pathology [31, 32].
Other non-hydrolytic enzymes also break down AEA including lipoxygenases 
and cyclooxygenases. These non-FAAH systems are very active at non-cannabinoid 
receptors although their importance in deactivation of AEA at cannabinoid recep-
tors has yet to be determined [20].
AEA is not the only ethanolamide that can bind to cannabinoid receptors. Other 
bioactive lipids in this class include numerous compounds including palmitoyletha-
nolamide (PEA) and oleoylethanolamide (OEA) bind to the CB1 receptor. Each of 
these ligands has distinctive physiological effects associated with them. PEA is asso-
ciated with several indications including use as an anti-inflammatory or analgesic, 
while OEA appears useful as an appetite suppressant to reduce body weight [33, 34].
Both PEA and OEA are polyunsaturated fatty acids with multiple double bonds 
within the long chain. Other polyunsaturated fatty acids have also been reported to 
have agonist activity for the cannabinoid receptors. Only AEA, among the saturated 
and monounsaturated fatty acids, has been found to have affinity for the cannabi-
noid receptors.
4. 2-Arachidonylglycerol (2-AG): the second endocannabinoid
2-arachidonylglycerol (2-AG) is a monoacylglycerol that incorporates arachi-
donic acid at the 2 position of the glycerol backbone. This molecule serves the dual 
function of a lipid intermediary while also functioning as a chemical messenger 
within the ECS. Although this endocannabinoid was discovered later than AEA, 
2-AG is several hundred fold more common in the CNS compared to AEA and is a 
full agonist to both the CB1 and CB2 receptors.
There are two major pathways for the synthesis of 2-AG. Similar to AEA, initia-
tion of the process to manufacture 2-AG requires an inflow of calcium2+ into the 
neuron. The primary pathway for synthesis involves a precursor, phosphatidylino-
sitol, converted by phospholipaseβ or phospholipaseγ, to the intermediary lipid 
1,2-diacylglycerol (1,2-DAG). The 1,2-DAG is then hydrolyzed by a DAG lipase to 
form the endocannabinoid 2-AG.
There is a secondary pathway also available that involves the production of the 
intermediary 2-arachidonyl lysophospholipid. Once 2-arachidonyl lysophospho-
lipid is available, this lysophospholipid in the presence of the enzyme lysophospho-
tase-C (LYSOPLC) is rapidly converted to 2-AG.
The breakdown of 2-AG also occurs through a primary pathway but several 
minor alternatives are also present. Hydrolysis of 2-AG by monoacylglycerol lipase 
(MAGL) is the most common pathway and involves the cleavage of the ester bond 
within the 2-AG structure to form arachidonic acid and glycerol. There are at least 
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two forms of MAGL that have been found in rodent and rabbit models. In compari-
son to the small amounts of AEA and its associated degradative enzymes, 2-AG is 
widely distributed throughout the CNS along with its synthetic and degradative 
enzymes. Perhaps because of the breadth of distribution of 2-AG in the CNS, some 
overlap with AEA occurs. However, a more important distinction is that MAGL is 
found only in the presynaptic neuron and degradation of 2-AG occurs after release 
from the presynaptic cannabinoid receptor. AEA, in comparison, after its release 
from the presynaptic cannabinoid receptor must traverse the synaptic cleft and 
enter the postsynaptic neuron where it is broken down by the NAE degrading 
enzyme FAAH [17, 35, 36].
The development of genetically modified mice deficient in MAGL along with 
the synthesis of MAGL inhibitors have provided useful tools to study the proper-
ties of 2-AG. Use of these ligands that block the synthesis of MAGL have revealed 
elevations of this endocannabinoid, especially in the brain and to a lesser extent 
multiple organs in the body including the heart, liver, kidney, and brown adipose 
tissue. Although 2-AG is the major endocannabinoid that binds to the cannabinoid 
receptors in brain, it clearly also serves an important role in the the regulation of 
chemical signaling in other organ systems. When the breakdown of 2-AG appears is 
impaired due to these receptor anatagonists or genetic manipulations, arachidonic 
acid is significantly reduced in the brain. This suggests that the production of 2-AG 
serves an important role not just in the formation of an endocannabinoid but also in 
the in the production of proinflammatory molecules [37].
Other alternative routes for 2-AG degradation are also available. 
Cycloxygenase-2 (COX-2) and lipoxygenases are secondary enzyme systems that 
also reduce 2-AG. COX-2 serves an important role in the inflammatory process and 
converts arachidonic acid to prostaglandins. Lipoxygenases oxidizes polyunsatu-
rated fatty acids and these are non-heme, iron-containing enzymes that are found 
in a broad range of eukaryotes. They are known to be involved in the metabolism of 
the eicosanoids including the prostaglandins [37].
5. Endocannabinoid-GABA regulation of chemical messaging
In the 1990s, the phenomenon of “depolarization-induced suppression of 
inhibition” (DSI) was first reported in the purkinje cells of the cerebellum [38] 
and later in hippocampal pyramidal cells [39]. DSI occurs through the activation 
of the CB1 receptor and is considered the classic example how endocannabinoids 
regulate neuronal behavior through retrograde signaling and suppression of GABA 
release. The CB1 receptor is densely expressed on the GABA presynaptic neurons 
that are abundantly found in the cerebral cortex, hippocampus and amygdala and 
are essential for higher cortical functions including learning and memory. Small 
interneurons release GABA and communicate with the larger purkinje cells and 
pyramidal neurons. This interaction moderated by the release of GABA results in 
hyperpolarization of the larger post-synaptic cell and subsequent inactivation. 
Activation of the CB1 receptor located on the presynaptic interneuron inhibits the 
release of GABA and thus suppresses the inhibition of the larger cells. It is now well 
established that this inhibition of GABA release from the interneuron is the result of 
retrograde communication from the activated postsynaptic cell to the presynaptic 
GABA-containing interneurons through the release of endocannabinoids that 
facilitate an increase of intracellular calcium2+ and the initiation of the DSI. Other 
cannabinoid agonists in addition to endocannabinoids are also known to block 
interneuron release of GABA through depolarization-induced suppression of inhi-
bition. Presynaptic CB1 antagonists, such as rimonabant, have also been reported 
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to block the effect of CB1 receptor activation further establishing the critical role of 
retrograde modulation of chemical signaling through the ECS [22]. Thus, inhibition 
of GABA release is governed through depolarization of the presynaptic neuron by 
endocannabinoid binding to the presynaptic CB1 receptor [40, 41].
A few years after the discovery of DSI, presynaptic stimulation of CB1 through 
retrograde transmission of endocannabinoids was found to also occur with 
excitatory neurons and the phenomenon was termed “depolarization induced 
suppression of excitation”(DSE). Unlike DSI and the inhibition of GABA release, 
DSE inhibits the release of excitatory neurotransmitters including glutamate 
through a similar retrograde release of endocannabinoids. Although initially 
discovered the inactivation of Purkinje cells, DSE has also been observed in other 
regions of the brain although the role of endocannabinoids in these areas is less 
well established [42].
Dependent upon the presynaptic neurotransmitter, stimulation of presynap-
tic CB1 receptor through retrograde release of endocannabinoids moderates the 
communication between cells. This changing effect of the endocannabinoids on 
GABA and glutamate release and the shaping of synapses occrs through a process 
called synaptic plasticity. Activation of a single synapse is usually insufficient to 
activate the post-synaptic cell and multiple synapses must fire simultaneously. The 
coordination and magnitude of the synaptic communication determines the change 
of voltage in the post-synaptic cell and the strength of the signal. Reductions in 
the number of presynaptic cells or incoordination of firing results in weakening of 
the signal.
The strengthening of synapses over time is termed long term potentiation and 
requires coordination of firing of the pre and post synaptic cells within a window 
of 20 msec. Cellular firing outside the temporal window weakens the synapse and 
reduces the voltage difference over time and is referred to as long term depression.
There is a balance in the regulation of excitation and inhibition that allows the 
brain to physically adapt for learning and memory [43]. Generally these changes are 
incremental and occur continuously at the synaptic level through a process termed 
synaptic plasticity [44].
Although glutamate has received a great deal of attention in the process of 
neuroplasticity, GABA also plays an important, or perhaps equal, role in the 
adaptation of the nervous system. Changes in neuronal activity and excitation by 
glutamate release may initiate off-setting activation of inhibitory inputs through 
GABA interneurons. In both activation and inhibition of the synaptic signal, 
retrograde release of endocannabinoids through DSI and DSE likely mediates 
synaptic depression [43].
6. GABA and the tale of two cannabinoids
The endocannabinoid system maintains homeostatsis in the CNS primarily 
through activation of the CB1 receptor. This receptor is also responsible for the 
well-known behavioral and physiological effects of the phytocannabinoids. The 
mechanism of how this modulation of the CNS occurs is by retrograde signaling 
through activation of the CB1 receptor. As noted earlier, the ECS and GABA neurons 
are collocated in many areas of the brain and this close proximity may explain how 
CB1 binding influences the GABA system. The cortex, hippocampus, hypothalamus 
and cerebellum are areas in the brain where this overlap of the ECS and GABA is 
especially prominent.
There are several preclinical studies that have examined the inhibition of GABA 
release in the presence of cannabinoid agonists. One early in vitro study employing 
Pharmacognosy - Medicinal Plants
10
an investigational synthetic cannabinoid agonist (WIN 55,212–2) on hippocampal 
interneurons found a diminuition of GABA release from the neurons after expo-
sure. In another in vitro study the same investigational agent plus a second experi-
mental cannabinoid agonist (CP-55940) were evaluated in rodent corpus striatum 
and found a dose-dependent reduction in GABA release.
Acute administration of the phytocannabinoid THC has also been studied. In 
an in vivo electrophysiological project after treatment, extracellular GABA in the 
prefrontal cortex was found to be significantly reduced compared to baseline. 
Different areas of the rodent brain were studied including the corpus striatum, and 
prefrontal cortex. One study reported different findings that THC and a synthetic 
cannabinoid failed to have effects on GABA synthesis and uptake in the globus 
pallidus in substantia nigrae of the rodent brain [45, 46].
Two other studies also evaluated the effect of THC on GABA release in rodent 
models. One evaluated THC alone and reported a dose-dependent reduction in 
GABA uptake in the rat globus pallidus [47, 48].
The abundance of CB1 receptors on presynaptic neurons and their relationship 
to the strength of inhibition was assessed in a study of cholecystokinin (CCK) 
expressing GABA interneurons in the hippocampus. Earlier studies had demon-
strated that the number of ion-channel-forming AMPA receptors could predict the 
magnitude of the postsynaptic response [49, 50] and that more GABA receptors 
were associated with greater inhibition. However, CB1 receptors are GPCR and 
operate through different mechanisms including modulation of voltage-gated Ca2+ 
and K+ channels and second messenger systems. Using the CB1 receptor antagonist 
AM251, the effect of activation was measured in basket cells and dendritic-layer 
innervating (DLI) cells. Basket cells have a significant higher expression of CB1 
receptors and DLI have significantly less receptor density. The CB1 receptor antago-
nist AM251 increased the action-potential inflow of Ca2 by 54% in basket cells but 
not in DLI. However, this increase was significantly reduced from the expected 
effect of the large number of receptors. A CB1 agonist decreased Ca
2+ independent 
from the CB1 receptor expression. Collectively this suggests that only a subpopu-
lation of CB1 receptors in close proximity to the Ca
2+ channel participate in the 
endocannabinoid modulation of GABA release [51].
Another study evaluated the effect of exposure to cannabinoids in adolescent 
rats. Using electrophysiological and immunohistochemical techniques, early-, 
mid- and late adolescent rats were treated with a CB1 agonist (WIN). Early and 
middle adolescent rats were found to exhibit significant disinhibition of prefrontal 
cortex (PFC) behaviors at the later adult stage. This result was reversed when the 
adolescent rat was infused with the positive allosteric modulator GABAA agonist 
Indiplon. This response suggests that at certain stages of development exposure to 
cannabinoid agonists may be critical in the downregulation of GABA in the PFC 
and expressed in the adult stage of maturation [52].
A recent review summarized the literature on the interaction of endocannabi-
noids and neurotransmitters [22] although only a few have been reported for GABA. 
Administration orally or intravenously of the endogenous cannabinoid agonists 
including the endocannabinoids is technically difficult and their interpretation 
limited. On the other hand, phytocannabinoids can be smoked, ingested or applied as 
a topical with significant absorption and physiological effects mediated through can-
nabinoid receptors. In one report of adolescents, thirteen habitual users of cannabis 
were compared to sixteen non-canabis normal controls in a study using standard 1H 
MRS techniques performed on a MAGNETOM trio whole body MRI/MRS system to 
determine GABA metabolism in the anterior cingulate cortex (ACC) [53]. reported 
reduced levels of GABA in the anterior cingulate cortex (ACC) of adolescents that 
were habitual users of marijuana when compared to match controls. The ACC 
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surrounds the anterior area of the corpus callosum and communicates with the 
prefrontal cortex and parietal lobe in addition to deeper limbic structures including 
the amygdala, nucleus accumbens and hippocampus. It is well established that GABA 
plays an important role in the maturation of these area in the adolescent brain and 
disruption of this process may result in neuropsychiatric and substance abuse issues 
later in life.
Results of the MRS scans revealed significantly lower levels of ACC GABA 
activity in adolescents that habitually used cannabis. Reduced ACC glutamate levels 
in adolescents that habitually used cannabis had been reported in an earlier study 
[54] with MRS imaging and in this follow-up report these findings paralleled the 
reduction in glutamate with a similar reduction of GABA.
Enhancement of GABA activity has been proposed as a therapeutic approach to 
the treatment of cannabis use. In one randomized clinical trial (RCT) fifty patients 
with cannabis dependency were treated with Gabapentin 1200 mg/day or placebo 
for twelve weeks. Compared to placebo, the study reported significant reduced 
use of cannabis measured by several assessments including urine drug screens. 
Gabapentin is a structural analog of GABA and was initially thought to act on the 
GABA system. Later studies demonstrated that Gabapentin does not alter GABA 
activity or receptors although it may increase GABA synthesis and non-synaptic 
GABA release [55].
In the first of two studies, the GABA reuptake inhibitor Tiagabine (Gabitril), 
was assessed in eight cannabis users and compared when combined with oral THC. 
THC was dosed at 30 mg p.o. and tiagabine at 6 and 12 mg p.o.. Subjects were 
trained to use established drug-discriminationprocedures to identify placebo and 
drug conditions, blinded to the study condition and were informed they would 
receive placebo, THC and tiagabine, alone or in combination during the study. 
Tiagabine was found to enhance the discriminative-stimulus, self-report and 
performance results when given with THC and to produce similar outcomes when 
administered alone [56].
In a subsequent study the investigators replaced tiagabine with baclofen and 
repeated the trial. In contrast to tiagabine, baclofen is a selective GABAB agonist but 
has not effect on the GABAA. Results of both studies were similar suggesting that 
GABAB receptors are involved at least in part with the effect of elevated GABA on 
cannabinoid-related behaviors [57].
The authors commented that although GABAB enhanced the effects of THC, 
they could not rule out that accentuation of GABA at GABAA receptors could also 
contribute to the outcome.
In addition to evaluation of the ECS and GABA through pharmacological 
enhancement of GABA, an interesting clinical study reporting that pharma-
cological-induced deficiency of GABA increased the effects of THC in several 
psychiatric assessments. Using normal subjects, this double-blind, placebo-
controlled study evaluated flumazenil, an antagonist and partial inverse 
agonist of the GABAa receptor, against intravenous THC or placebo. Blocking 
the GABAa receptor with flumazenil accentuated the psychological effects of 
THC including psychoses and anxiety and a decrease in the THC-induced P300 
amplitude [58].
Through imaging studies of the ECS, manipulation of the synthesis and deg-
radation of endocannabinoids, and pharmacological interventions much has been 
learned about the cannabinoids since the initial discovery of of the first cannabi-
noid receptor CB1 in 1988 [59]. The ECS plays a major role in the maturation and 
homeostatsis of the CNS and activation of the CB1 receptor is the primary initiating 
event. Modulation of other neurotransmitter systems including GABA can then 
occur through retrograde transmission [60].
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Ligands other than the endocannabinoids also bind to CB1 and CB2 receptors and 
much can be learned through observation of the effects of these non-endocannab-
inoids. Although phytocannabinoids, evolved through time in the plant kingdom 
and differ significantly from endocannabinoids, the overlap in affinity for can-
nabinoid receptors offer additional means to study the modulation by the ECS and 
neurotransmitter systems.
Phytocannabinoids are produced in the plant C. sativa (cannabis) and are C21 
terpenophenolic molecular ring structures grouped into eleven classes. Currently 
about 120 different phytocannabinoids have been identified in cannabis and 
comprise approximately 24% of the weight of the plant. The first class of phytocan-
nabinoids is the most common (approximately 17%) and contains the psychoactive 
THC. Variations in the growth of the plant C. sativa including growing conditions 
and sunlight, geography, processing and storage, and plant variety can all sig-
nificantly alter the proportion of each chemical class. For this reason, cannabis is 
constantly in change and this variation can influence the pharmacological proper-
ties of different cannabis extracts [61].
There are several large epidemiological studies of phytocannabinoid effects on 
the ECS. Although banned in many areas, Cannabis is the most used illicit drug 
globally with an estimated 3.8% (182.5 million) of the global population exposed to 
cannabis [62, 63]. Within the United States, the estimated exposure is even higher 
with 8.4% (22.2 million) of the population reported to have used cannabis in one 
year. With relaxation of laws and greater duration of use combined with the change 
in composition and potency of cannabis, real world studies can provide us impor-
tant information in understanding the function of the ECS system and the effects of 
disruption of normal processes.
Among the most important epidemiological studies are reports of exposure to 
cannabis of pregnant women and the effects on their offspring. In a recent study 
it was estimated that 5.2% (115,000) of pregnant women are exposed during their 
preganancy. Some of these women likely use cannabis unaware of their pregnancy 
and inadvertently expose the first trimester fetus to THC when the nervous system 
is first initiated. Others may choose to use THC later in pregnancy believing it is a 
safe remedy for pregnancy-associated nausea and vomiting while neurotransmit-
ter systems are evolving. Others may just believe that cannabis use is safe and be 
unaware of the potential hazard to the unborn [64].
As with many drugs, however, cannabinoids carry significant safety concerns 
for pregnant women and as a lipophilic molecule easily traverse the placenta into 
the fetal bloodstream. Animal studies have shown a clear association between can-
nabinoids and lower birth weight. In humans, several large, well-conducted studies 
have explored the short- and long-term effects on fetal, child and adolescents and 
possible teratogenicity of prenatal cannabis exposure on fetal development (Hurd et 
al. 2005).
The Ottawa Prenatal Prospective Study (OPPS) was a large, epidemiological 
study of 291 expectant, middle class Canadian women. Within this group of expect-
ant mothers, 20% used cannabis sometime during their pregnancy. All subjects 
were evaluated during their pregnancy and for the first six years using standardi-
azed neuropsychological tools.
At birth, there were observations made of increased startle reflex in children 
exposed in utero to cannabis, but no significant change in weight or increased 
presence of congenital malformations. By age four, however, behavioral changes 
including decreased visual performance, attention, and memory were apparent. In 
older children, impaired executive function was reported [65, 66].
In 1991 a second longitudinal study named the Maternal Health Practices and 
Child Development Study (MHPCD) was reported on 519 expectant mothers 
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and live born infants. Unlike the earlier study in Ottawa, expectant mothers were 
largely lower class economically with poorer prenatal care. Expectant mothers 
were evaluated at 4 and 7-month gestation offspring evaluated until young adult-
hood. Growth parameters including birth weight, head or chest circumference, 
and gestational age were analyzed at birth with no statistical differences noted 
between newborns with non-exposure in utero and in newborns with maternal use 
of cannabis. There was a small effect on decreased birth length in exposure the first 
two months and a positive effect on body weight with usage in the third trimester 
[67]. In a follow-up of the offspring in this study up to two decades later, prenatal 
maternal exposure to cannabis was found to result in a greater risk of cannabis use 
in their children at adolescence (38% before age 15). By age 22 in-utero cannabis-
exposed children were more apt to not complete high school (54.4% vs. 37.2% in 
controls), be unemployed (67.6% vs. 52.1%) and more likely to have been arrested 
(56% vs. 27.3%) [68].
The Dunedin study was a third, and more controversial, project conducted in 
New Zealand on 1037 individuals followed from birth to 38 years. One measure-
ment obtained over the course of the study was the evaluation of the association 
between cannabis use and neuropsychological outcomes. Neuropsychological 
assessments were obtained before the age when cannabis use occurred and 
changes studied. Cannabis use was obtained at age 13 and then at age 38 after 
a pattern of consistent use. It was found that there was an associated decline in 
IQ related to the frequency and length of exposure to cannabis. The greatest 
vulnerability appeared to occur with adolescent exposure. The authors found that 
persistent cannabis use was associated with neuropsychological decline broadly 
across domains of functioning, most significantly in the domains of executive 
functioning and processing speed. Study participants with more persistent canna-
bis dependence also showed greater IQ decline over the years, along with greater 
overall cognitive decline. Greater cognitive impairment was observed in those who 
began cannabis use in adolescence. The investigators also pointed out that cessa-
tion of cannabis use did not fully restore neuropsychological functioning in these 
adolescence-onset users [69, 70].
Another recent large, retrospective, cohort study of 661,617 pregnant women 
study conducted over six years in Ontario, Canada examined the association 
between self-reported cannabis use in pregnancy and any adverse maternal or 
perinatal outcomes. The investigators accounted for known confounding factors, 
such as tobacco use, in one of two cohorts by the use of a matched design analysis. 
The results showed that preterm birth rate, at less than 37 weeks’ gestation, for both 
the matched and unmatched cohorts were significantly higher in the women who 
reported cannabis use. The rate of preterm birth rate in the unmatched cohort was 
12.0% in cannabis users, compared to 6.1% in nonusers. In the matched cohort, 
the rate of preterm birth was 10.2% in cannabis users versus 7.2% in nonusers. A 
continuous increase in relative risk of preterm birth from cannabis exposure was 
observed between 34 to 36 6/7 weeks’ and 28 to 31 6/7 weeks’ gestation, respec-
tively. Because this type of increase was not observed for very preterm birth at less 
than 28 weeks’ gestation, it was conjectured that cannabis exposure may be more 
strongly associated with early and moderate preterm births versus very preterm 
births. Cannabis use in the subjects was also significantly associated with the fol-
lowing secondary outcomes: small for gestational age, placental abruption, transfer 
to neonatal intensive care, and 5-minute Apgar score of less than 4 [71].
Both the OPPS and MHPCD studies were consistent in demonstrating behav-
ioral and cognitive impairment years after exposure to cannabis in-utero. The 
Dunedin study also reported decline in IQ related to cannabis exposure begin-
ning in adolescence. Collectively, all three studies report important deficits that 
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emerge over time in child and adolescent maturation. A limitation of these stud-
ies, however, is the continuing social acceptance of cannabis use and increasing 
potency of THC.
To provide more current information, an NIH-initiative, the Adolescent Brain 
Cognitive Development (ABCD) Study is ongoing. This is a national, multisite, 
longitudinal cohort study that is prospectively following subjects from childhood 
through adolescence to explore the effects of substance use such as cannabinoids, 
among other experiences, on neurocognitive development. There are, of course, 
many challenges associated with long epidemiologic studies. Aside from participant 
loss and difficulty maintaining controls, the constant flux in the content of can-
nabinoid products over the years, namely the significant increases in the ratio of 
THC to CBD, presents significant inconsistency in comparing these long studies or 
predicting current risk.
7. Final comments
GABA is an amino acid concentrated within the CNS and is recognized as the 
major inhibitory neurotransmitter in the brain [1]. With the exception of a second, 
excitatory amino acid neurotransmitter glutamate, GABA is present in millimoles/
gm in brain tissue compared to nanomolar/gm concentrations of the other classic 
neurotransmitters [72].
The physiological effects of GABA do not occur in isolation. The functional rela-
tionship beween the two systems begins after the release of GABA from an activated 
presynaptic neuron and stimulation of the postsynaptic cell. Endocannabinoids are 
then manufactured on-demand and released to bind to cannabinoid receptors on 
the presynaptic membrane terminating the release of GABA.
The CB1 receptor is highly expressed in several regions of the brain including the 
forebrain, amygdala, hippocampus, substantia nigra and cerebellum. This receptor 
is frequently in GABA containing neurons and this overlap allows for close coordi-
nation and interaction between the two systems. As a result, the ECS provides an 
important feedback to the GABA system and participates in the maturation of the 
CNS and the function of the adult brain [72, 73].
The GABA system and the ECS, similar to all neurotransmitters, are limited 
to brief synaptic activity at discrete locations and are quickly terminated through 
either enzymatic breakdown or reuptake mechanisms. GABA is stored in presyn-
aptic vesicles and released after excitation by an action potential into the synapse to 
stimulate the postsynaptic cell. The endocannabinoids, in contrast, are synthesized 
in the postsynaptic membrane on demand only after the cell is stimulated. Upon 
release, the endocannabinoid moves in a retrograde direction across the synapse 
and binds to the CB1 receptor on the presynaptic neuron. Once the endocannabi-
noid is bound to the CB1 receptor, the release of neurotransmitters from the presyn-
aptic neuron is terminated.
How endocannabinoids work in moderating GABA is introduced in the discus-
sion of depolarization induced suppression of inhibition (DSI). This is a critical 
concept on how the chemical signal with GABA release is moderated by the activa-
tion of the CB1 receptor. Although less established, activation of this cannabinoid 
receptor may also activate another amino acid transmitter glutamate through a 
similar mechanism termed depolarization induced suppression of excitation (DSE).
Several preclinical studies of ECS and GABA in this chapter followed the initial 
papers on DSI and DSE and the concept of CB1 receptor activation influencing the 
release of GABA (and potentially glutamate). Although for technical reasons it has 
not been possible to study the effect of AEA and 2-AG directly, these studies chose 
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to utilize several laboratory-created CB1 agonists under investigation or the phy-
tocannabinoid THC. No matter the source of the agonist, the findings consistently 
found that stimulation of the CB1 receptor reduced the release of GABA.
From these studies it is apparent that activation of the CB1 receptor is not 
exclusive to endocannabinoids. As discussed earlier, the plant C. sativa produces 
phytocannabinoids including THC that also are agonists and partially bind to the 
CB1 receptor [74]. These molecules evolved in the plant kingdom for evolutionary 
imperatives that are incongruent with the evolution of the ECS in animals. Although 
they differ significantly from the endocannabinoids in chemical structure, synthe-
sis, degradation, phytocannabinoids including THC and CBD are of great interest 
since they have CB1 receptor activity and similarly influence the release of GABA. 
This affinity is likely coincidential yet provides additional information on the inter-
play between the physiological functions regulated by GABA and activation of CB1.
Earlier in this chapter several large epidemiological studies were reviewed 
reporting the effects of cannabis on the development of the nervous system in 
utero to maturity. These studies are informative because they describe the effects 
of cannabinoids on the developing nervous system and adult where GABA plays 
an important role. From these reports it is likely that early maternal exposure to 
phytocannabinoids results in impairment in the offspring through disruption of the 
development of the nervous system with behavioral abnormalities appearing later 
in life [65, 68, 75, 76].
There are obvious limitations in large scale studies since In normal circum-
stances ECS and GABA collaborate in limited and localized coordination in develop-
ment. Phytocannabinoids act systemically throughout the body and are not limited 
to discrete synapses. In addition, since phytocannabinoids are lipid soluble, seques-
tered in fat tissue, and broken down by hepatic enzymes, the location and duration 
of exposure to phytocannabinoids differs from the brief, focused synaptic interac-
tion between GABA and the endocannabinoids. Nevertheless, these large studies 
of cannabis use provide important information on how phytocannabinoids may 
disrupt GABA function that may be reflected in the abnormalities reported in these 
larg scale studies. Cannabis is regarded by many as relatively ‘safe’ and is becoming 
‘legal’ in many areas. However, other ‘safe’ and ‘legal’ drugs including nicotine and 
alcohol are associated with serious public health concerns. These studies give us 
insight into the possible risks associated with using phytocannabinoids and influ-
encing the communication between GABA and the endocannabinoids.
The interaction of GABA and the ECS is important for normal physiological 
function. As our knowledge of this modulation of the CNS advances, additional 
knowledge and treatments will likely emerge that will provide unexpected benefits 
to patients. However, epidemiological studies of exposure to cannabis also provide 
important information they reveal the disadvantages and risks of disruption of the 
GABA-ECS systems. As increased access and duration of usage evolve, we will learn 
more of the benefits, and risks, of cannabiods.
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